Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
boston blog main
boston top stories
clinical trials
life sciences
national blog main
boston
allergan
crispr
cynthia collins
editas medicine
gene editing
new york blog main
san francisco blog main
abbvie
agios pharmaceuticals
alzheimer's disease
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
bluebird bio
cancer
cancer drugs
david e. shaw
deals
drug discovery
drugs
duchenne muscular dystrophy
dyne therapeutics
enasidenib
facioscapulohumeral muscular dystrophy
fda
gene therapy
investing
ipo
ivosidenib
joshua brumm
kaleido biosciences
katrine bosley
What
experimental
4
×
medicines
editas
editing
gene
genetic
humans
ipo
abbvie
ago
allergan
alliance
biotech
biotechs
blessing
bosley
ceo
check
clinical
company’s
considering
course
crispr
cusp
data
depart
development
discover
diseases
drug
dyne
early
exits
expected
eyes
growing
handiwork
having
helped
internal
Language
unset
Current search:
experimental
×
biotech
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial